Studies are currently taking place to identify the effectiveness of certain treatments on mesothelioma patients.
The Mesothelioma and Radical Surgery Trial (MARS)
Although it is known that radical surgery will not cure a sufferer of mesothelioma many believe it can slow down the development of the disease. It means patients may feel better in the medium to long term than they would if they did not have the surgery.
The MARS trial is being conducted to try to prove this and examine the role of Extrapleural Pneumonectomy (EPP) in treating the symptoms of Mesothelioma. Sponsored by Guy’s and St.Thomas’ NHS Foundation Trust, it will aim at treating 50 patients who are thought to be suitable for the trial.
EPP involves removing the whole lung and pleura, together with the diaphragm and the side of the pericardium (the sac around the heart), in one piece. After removal of the tumour the diaphragm and pericardium are then reconstructed with artificial patches.
The purpose of MARS is to find out if the operation, along with chemotherapy and a six-week course of radiotherapy increases life expectancy and quality of life compared to other standard treatments bearing in mind the short term risk factors of the surgery itself.
The UK National Mesothelioma and Lung Cancer Study (MALCS)
This study was set up 6 years ago to identify the risks that certain occupations and work practices, particularly those involving asbestos exposure, on the development of mesothelioma and other lung cancers.
It has been identified that workers in dockyards, ships, asbestos factories, power generators and producers of insulation were all at an increased risk of getting mesothelioma. Of those studied, who have been affected by the disease, 25% had worked in construction within these industries.
Results have already identified that it depends on the age of the person when exposed to the asbestos and their particular occupation. It also identified that even people living with workers who had been exposed to asbestos may be affected by the disease.
The study is open until 2015 and patients meeting certain criteria can apply to take part via a postal questionnaire. For more information, contact the study team via email MALCS@icr.ac.uk or telephone: 0208 722 4298.